Novo Nordisk Raises Bid Again for Metsera as Takeover Battle with Pfizer Heats Up

Novo Nordisk boosts its offer for obesity startup Metsera, countering Pfizer’s $86.20 per share bid. The bidding war is nearing its end as both pharma giants race to dominate the booming obesity drug market.